a public good project by the
Synthesis
Company
of California

© 2026

Edwin Clark | doi.page

0 works0 citations0 h-index

Edwin Clark

AstraZeneca (South Korea)(KR)AstraZeneca (United States)(US)

Publications by Year

Research Areas

Protein Degradation and Inhibitors, Renal cell carcinoma treatment, Multiple Myeloma Research and Treatments, HER2/EGFR in Cancer Research, Chronic Myeloid Leukemia Treatments

Most-Cited Works

→ Integrins and Signal Transduction Pathways: the Road Taken(1995)2,977 cited
→ Genomic analysis of metastasis reveals an essential role for RhoC(2000)1,432 cited
→ Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab(2007)1,126 cited
→ Integrin-mediated Signals Regulated by Members of the Rho Family of GTPases(1998)606 cited
→ Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer(2004)568 cited
→ Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia(2018)480 cited

→ Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection(2007)

343 cited

→ Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin alpha IIb beta 3.(1994)223 cited

→ Redistribution of activated pp60c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets.(1993)219 cited

→ Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma(2003)176 cited